摘要:
Methods for producing a compound of formula (k1) or (k2) by reducing a dihydronapthalene amide compound of formula (i); with hydrogen gas in the presence of a ruthenium catalyst of formula (j1) or (j2); Ru(Z) 2 (L) = (j1), Ru(E)(E')(L)(D) = (j2); wherein m, n, Ar, Y, R 1 E, E', D, Z and L are as defined herein.
摘要:
The present invention relates to a new process for the preparation of macrocyclic HCV protease inhibitor compounds of the formula (XXII) wherein R 1 is an amino protecting group and X is halogen by way of a ring closing metathesis approach.
摘要:
The invention relates to a process for the preparation of pyrido[2, 1-a] isoquinoline derivatives of the formula (I), weherein R2, R3 and R4 are as defined in the specification, comprising the steps of: a) catalytic asymmetric hydrogenation of an enamine of the formula (II), wherein R1 is lower alkyl, in the presence of a transition metal catalyst containing a chiral diphosphane ligand, b) introduction of an amino protecting group Prot and c) amidation of the ester to form an amide of formula (V), wherein R2, R3, R4 and Prot are as defined in the specification.
摘要:
Disclosed are novel metathesis catalysts of the formula (I), a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis.
摘要:
The present invention relates to a novel process for producing a δ-lactone of the formula (I) using an acyl halide of the formula (1) wherein R?1, R2, R3¿ and X are described herein, as well as novel intermediates. In particular, the present invention relates to a process for enantioselectively producing the (R)-δ-lactone.
摘要:
The invention relates to novel metathesis catalysts of the formula (I) a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis. The invention further relates to a process for the manufacture of a macrocyclic compound of formula (VII) which have the potential to be useful as HCV protease inhibitors.
摘要:
The present invention relates to a process for the preparation of cis substituted cyclic β- aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme (Formula I, II) wherein X is -C(R)(R')-, -N(R')-, -O-, -S(O)0-, C(O)N(R'), -N(R')C(O)- or -C(O)-; R and R' are independently from each other hydrogen, C1-7-alkyl, C1-7-alkyl substituted by halogen, C1-7-alkoxy, hydroxy or -(CH2)P-Ar; R' is hydrogen, C1-7-alkyl, C1-7-alkyl substituted by halogen, -S(O)0-C1-7-alkyl, -S(O)0-Ar, -S(O)0-NRR', -(CH2)P-Ar, -C(O)-C1-7-alkyl, -C(O)-Ar, -C(O)-NRR' or -C(O)O-C1-7-alkyl; Ar is aryl1 or heteroaryl1; n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; o is 0, 1 or 2; p is 0, 1, or 2; and corresponding salts thereof.
摘要:
The present invention is concerned with a novel process for the preparation of compounds of formula (I) comprising catalytic asymmetric hydrogenation of a compound of formula (II) in the presence of a catalyst comprising ruthenium and a chiral diphosphine ligand or comprising rhodium and a chiral diphosphine ligand, wherein R1, R2, R3 and R4 are as defined in the specification and claims. The compounds of formula (I) and the corresponding salts and/or esters are pharmaceutically active substances.
摘要:
The present invention is concerned with a novel process for the preparation of compounds of formula (I) and optionally converting a compound of formula (I) into a pharmaceutically acceptable salt, wherein R1 and R 2 are as defined in the description and claims. The compounds of formula (I) and the corresponding salts, e.g. the sodium salts, are pharmaceutically active substances.